Article

Developing an Aggregator Mechanism for Late-Stage Clinical Trials of Neglected Disease Product Candidates

2020-10-21

Abstract excerpt

There have been significant improvements in recent years in the early stage development of products for poverty-related and neglected diseases (PRNDs). However, there are still major challenges in the funding of late-stage clinical trials of candidate products for these diseases. For vaccine development specifically, Rappuoli and colleagues recently concluded that “these improvements in the early development proce...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 47a111ce-df96-58f6-81b6-eafa8edf0cec
DOI: 10.2139/ssrn.3711578

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Developing an Aggregator Mechanism for Late-Stage Clinical Trials of Neglected Disease Product CandidatesDOI 10.2139/ssrn.3711578Read

To fully tackle the gang of four, needs-driven R & D is essential. Authors' reply [6].Semantic proximity Read

The role of NIH funding in vaccine readiness; foundational research and NIH funding underlying candidate SARS-CoV-2 vaccinesSemantic proximity Read

Living mapping review of global research funding for infectious diseases with a pandemic potential – Pandemic PACT Grant TrackerSemantic proximity Read

Living mapping review of global research funding for pandemic-prone infectious diseases– Pandemic PACT Grant TrackerSemantic proximity Read

The TB vaccine clinical trial centre directory: an inventory of clinical trial centres in sub-Saharan AfricaSemantic proximity Read

DRUG DISCOVERY AND DEVELOPMENT FOR NEGLECTED TROPICAL DISEASESSemantic proximity Read

Technologies for the design, discovery, formulation and administration of vaccines.Semantic proximity Read

The Yellow Fever Vaccine Journey: Milestones and Future DirectionsSemantic proximity Read

The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 CountriesSemantic proximity Read

Highly Pathogenic Avian Influenza Vaccines: challenges for innovation, technological development and pandemic preparednessSemantic proximity Read

Comparative epidemiology of ivermectin and vaccines against Delta variant based on real-world data and hypothesized mechanisms of ivermectin immunological actionSemantic proximity Read

Preparing for Next-Generation Antimalarials in Nigeria: A Pre-Introduction Readiness Assessment with Focus on Infant-Friendly Formulations and Emerging TherapiesSemantic proximity Read